Myungmoon Pharm Co Ltd banner
M

Myungmoon Pharm Co Ltd
KRX:017180

Watchlist Manager
Myungmoon Pharm Co Ltd
KRX:017180
Watchlist
Price: 1 823 KRW -1.51% Market Closed
Market Cap: ₩61.9B

Myungmoon Pharm Co Ltd
EPS (Diluted)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Myungmoon Pharm Co Ltd
EPS (Diluted) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company EPS (Diluted) CAGR 3Y CAGR 5Y CAGR 10Y
M
Myungmoon Pharm Co Ltd
KRX:017180
EPS (Diluted)
₩43
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Yuhan Corp
KRX:000100
EPS (Diluted)
₩2.6k
CAGR 3-Years
27%
CAGR 5-Years
-3%
CAGR 10-Years
3%
SK Biopharmaceuticals Co Ltd
KRX:326030
EPS (Diluted)
₩3.4k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Hanmi Pharm Co Ltd
KRX:128940
EPS (Diluted)
₩13.4k
CAGR 3-Years
27%
CAGR 5-Years
68%
CAGR 10-Years
0%
S
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
EPS (Diluted)
₩226
CAGR 3-Years
-5%
CAGR 5-Years
N/A
CAGR 10-Years
-9%
C
Caregen Co Ltd
KOSDAQ:214370
EPS (Diluted)
₩411
CAGR 3-Years
-10%
CAGR 5-Years
-33%
CAGR 10-Years
N/A
No Stocks Found

Myungmoon Pharm Co Ltd
Glance View

Market Cap
61.9B KRW
Industry
Pharmaceuticals

MYUNGMOON Pharm Co., Ltd. engages in the manufacture and sale of pharmaceutical products. The company is headquartered in Hwaseong, Gyeonggi-Do. The company went IPO on 2008-07-10. Co., Ltd. is a Korea-based company mainly engaged in the manufacture of pharmaceuticals. Its products include ethical (ETC) drugs and over the counter (OTC) drugs. Its ETC drugs include anesthetic agents, digestive system drugs, rheumatoid arthritis remedies, central nervous system drugs, circulatory drugs, anti-depressant agents, anti-diabetic agents, antibiotics, hormone agents, narcotics and drugs for dermatology systems. Its OTC drugs include antinauseant agents, hepatic agents, immunologic agents, antidiarrheal agents, skin external preparations, antiallergic agents, muscle relaxants, cold drugs and parasiticides. The firm is also involved in the operation golf courses. January 2, 2012, the Company completed the merger with its wholly owned subsidiary.

Intrinsic Value
3 234.65 KRW
Undervaluation 44%
Intrinsic Value
Price ₩1 823
M

See Also

What is Myungmoon Pharm Co Ltd's EPS (Diluted)?
EPS (Diluted)
43.7 KRW

Based on the financial report for Sep 30, 2025, Myungmoon Pharm Co Ltd's EPS (Diluted) amounts to 43.7 KRW.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett